Icon (NASDAQ:ICLR) Releases Earnings Results, Beats Estimates By $0.01 EPS

Posted by Brenda Bartman on Jul 31st, 2026

Icon (NASDAQ:ICLR – Get Free Report) issued its earnings results on Wednesday. The medical research company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01, FiscalAI reports. Icon had a return on equity of 8.04% and a net margin of 3.99%.The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. Icon’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business earned $3.26 EPS.

Icon Stock Up 0.1%

ICLR opened at $165.61 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. The stock has a market cap of $12.68 billion, a price-to-earnings ratio of 38.86, a PEG ratio of 8.75 and a beta of 1.22. The company’s 50-day moving average price is $155.77 and its two-hundred day moving average price is $135.43. Icon has a twelve month low of $66.57 and a twelve month high of $203.91.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. EFG International AG purchased a new stake in Icon during the fourth quarter valued at about $27,000. Johnson Financial Group Inc. bought a new stake in shares of Icon during the third quarter valued at about $71,000. Quadrant Capital Group LLC purchased a new stake in Icon in the 3rd quarter worth approximately $78,000. Wilmington Savings Fund Society FSB raised its position in shares of Icon by 198.8% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 487 shares of the medical research company’s stock worth $89,000 after buying an additional 324 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analysts Set New Price Targets

ICLR has been the topic of a number of recent research reports. DA Davidson set a $164.00 price objective on shares of Icon in a research note on Monday, June 1st. Weiss Ratings cut shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Jefferies Financial Group reissued a “buy” rating and issued a $165.00 price objective on shares of Icon in a research note on Friday, May 29th. JPMorgan Chase & Co. lifted their target price on Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. Finally, TD Cowen raised their price objective on Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $168.87.

Read Our Latest Stock Analysis on Icon

Icon Company Profile

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.